Dominic Borie
Directeur Technique/Scientifique/R&D chez KYVERNA THERAPEUTICS, INC.
Fortune : 7 M $ au 30/04/2024
Profil
Dominic Borie is currently the President-Research & Development at Kyverna Therapeutics, Inc. He previously worked as an Executive Director at Allogene Therapeutics, Inc., a Medical Director at Amgen, Inc., a Senior Medical Director at Genentech, Inc., and a VP, Head-External Research & Development at Horizon Therapeutics Plc.
Dr. Borie also served as the Director-Transplantation Immunology Laboratory at Stanford University.
He holds a doctorate degree from The University of Texas at Austin and an undergraduate degree from North Carolina State University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 07/02/2024 | 449 210 ( 1,04% ) | 7 M $ | 30/04/2024 |
Postes actifs de Dominic Borie
| Sociétés | Poste | Début |
|---|---|---|
| KYVERNA THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 13/10/2022 |
Anciens postes connus de Dominic Borie
| Sociétés | Poste | Fin |
|---|---|---|
| Stanford University | Corporate Officer/Principal | - |
| AMGEN INC. | Directeur Technique/Scientifique/R&D | - |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Corporate Officer/Principal | - |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
| ALLOGENE THERAPEUTICS, INC. | Directeur/Membre du Conseil | - |
Formation de Dominic Borie
| The University of Texas at Austin | Doctorate Degree |
| North Carolina State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| KYVERNA THERAPEUTICS, INC. | Health Technology |
| ALLOGENE THERAPEUTICS, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
